4.5 Article

Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis

Journal

AMERICAN HEART JOURNAL
Volume 169, Issue 1, Pages 6-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2014.10.007

Keywords

-

Funding

  1. Roche Diagnostics
  2. St Jude Medical and Medtronic
  3. Brahms Thermofisher
  4. Abbott Diagnostics
  5. Abbott Laboratories
  6. Singulex, Inc
  7. Roche Laboratories
  8. Alere
  9. Beckman Coulter
  10. European Union
  11. Swiss National Science Foundation
  12. Swiss Heart Foundation
  13. Basel University
  14. University Hospital Basel
  15. Cardiovascular Research Foundation Basel
  16. Stanley Thomas Johnson Foundation
  17. Abbott
  18. Brahms
  19. Buhlmann
  20. Critical Diagnostics
  21. Nanosphere
  22. Pronota
  23. Roche
  24. Siemens
  25. 8sense
  26. National Institute for Health Research [06/302/19] Funding Source: researchfish

Ask authors/readers for more resources

Background Multiple studies have evaluated the diagnostic and prognostic performance of conventional troponin (cTn) and high-sensitivity troponin (hs-cTn). We performed a collaborative meta-analysis comparing cTn and hs-cTn for diagnosis of acute myocardial infarction (AMI) and assessment of prognosis in patients with chest pain. Methods MEDLINE/PubMed, Cochrane CENTRAL, and EMBASE were searched for studies assessing both cTn and hs-cTn in patients with chest pain. Study authors were contacted and many provided previously unpublished data. Results From 17 included studies, there were 8,644 patients. Compared with baseline cTn, baseline hs-cTn had significantly greater sensitivity (0.884 vs 0.749, P < .001) and negative predictive value (NPV; 0.964 vs 0.935, P < .001), whereas specificity (0.816 vs 0.938, P < .001) and positive predictive value (0.558 vs 0.759, P < .001) were significantly reduced. Based on summary receiver operating characteristic curves, test performance for the diagnosis of AMI was not significantly different between baseline cTn and hs-cTn (0.90 [95% CI 0.85-0.95] vs 0.92 [95% CI 0.90-0.94]). In a subanalysis of 6 studies that alternatively defined AMI based on hs-cTn, cTn had lower sensitivity (0.666, P < .001) and NPV (0.906, P < .001). Elevation of baseline hs-cTn, but negative baseline cTn, was associated with increased risk of death or nonfatal myocardial infarction during follow-up (P < .001) compared with both negative. Conclusion High-sensitivity troponin has significantly greater early sensitivity and NPV for the diagnosis of AMI at the cost of specificity and positive predictive value, which may enable early rule in/out of AMI in patients with chest pain. Baseline hs-cTn elevation in the setting of negative cTn is also associated with increased nonfatal myocardial infarction or death during follow-up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available